MA30061B1 - Preparation solide - Google Patents

Preparation solide

Info

Publication number
MA30061B1
MA30061B1 MA31045A MA31045A MA30061B1 MA 30061 B1 MA30061 B1 MA 30061B1 MA 31045 A MA31045 A MA 31045A MA 31045 A MA31045 A MA 31045A MA 30061 B1 MA30061 B1 MA 30061B1
Authority
MA
Morocco
Prior art keywords
insulin sensitizer
solid preparation
active component
coated
sensitizer
Prior art date
Application number
MA31045A
Other languages
English (en)
Inventor
Kenichiro Kiyoshima
Kenji Nakamura
Tetsuya Kawano
Masafumi Misaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37951491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30061(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA30061B1 publication Critical patent/MA30061B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention vise à fournir une préparation solide qui contient un sensibilisateur à l'insuline et un composant actif autre qu'un sensibilisateur à l'insuline et manifeste une conduite de dissolution d'un sensibilisateur à l'insuline semblable à celle d'un sensibilisateur à l'insuline provenant d' "une préparation solide contenant seulement un sensibilisateur à l'insuline à titre de composant actif". La préparation solide comprend "une partie contenant des particules enrobées dans laquelle les particules contenant un sensibilisateur à l'insuline sont enrobées avec du lactose ou un alcool de sucre" et "une partie contenant un composant actif autre qu'un sensibilisateur à l'insuline".
MA31045A 2005-12-22 2008-06-18 Preparation solide MA30061B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005370375 2005-12-22

Publications (1)

Publication Number Publication Date
MA30061B1 true MA30061B1 (fr) 2008-12-01

Family

ID=37951491

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31045A MA30061B1 (fr) 2005-12-22 2008-06-18 Preparation solide

Country Status (24)

Country Link
US (1) US8071130B2 (fr)
EP (1) EP1962811B1 (fr)
JP (1) JP5179363B2 (fr)
KR (1) KR20080080126A (fr)
CN (1) CN101384251B (fr)
AR (1) AR058605A1 (fr)
AU (1) AU2006328328B2 (fr)
BR (1) BRPI0620020A2 (fr)
CA (1) CA2633149C (fr)
CR (1) CR10032A (fr)
ES (1) ES2576258T3 (fr)
GE (1) GEP20115245B (fr)
HR (1) HRP20160679T1 (fr)
IL (1) IL191774A0 (fr)
MA (1) MA30061B1 (fr)
MY (1) MY149306A (fr)
NO (1) NO20083104L (fr)
NZ (1) NZ569071A (fr)
PE (1) PE20110019A1 (fr)
RU (1) RU2426530C2 (fr)
TW (1) TWI384985B (fr)
UA (1) UA91729C2 (fr)
WO (1) WO2007072992A2 (fr)
ZA (1) ZA200805147B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE534374T1 (de) 2006-05-23 2011-12-15 Takeda Pharmaceutical Orale zubereitung mit pioglitazon
TWI453041B (zh) 2007-02-01 2014-09-21 Takeda Pharmaceutical 固體型製劑
US8367115B2 (en) * 2007-08-27 2013-02-05 Asahi Kasei Chemicals Corporation Process for production of crystalline cellulose and tablets containing granules
MA33056B1 (fr) * 2009-01-23 2012-02-01 Hanmi Holding Co Ltd Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
MX337603B (es) * 2009-11-30 2016-03-10 Adare Pharmaceuticals Inc Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
CN101804056A (zh) * 2010-04-16 2010-08-18 山东新华制药股份有限公司 盐酸吡格列酮、格列美脲的复方片剂及制备方法
EP2611434A1 (fr) 2010-09-01 2013-07-10 Lupin Limited Composition pharmaceutique contenant de la metformine et de la pioglitazone
CA2811634C (fr) * 2010-09-21 2019-01-15 Intekrin Therapeutics, Inc. Compositions pharmaceutiques solides antidiabetiques
FR2966828B1 (fr) * 2010-11-02 2012-12-28 Roquette Freres Poudre de polysaccharide et de polyol, comprimable et de haute viscosite
WO2013034174A1 (fr) 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Préparations solides de pioglitazone et de glimépiride
WO2013034436A1 (fr) * 2011-09-08 2013-03-14 Hexal Ag Composition pharmaceutique à administration orale contenant une statine
WO2013058409A1 (fr) 2011-10-21 2013-04-25 Takeda Pharmaceutical Company Limited Préparation à libération prolongée
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
CN102641280A (zh) * 2012-04-23 2012-08-22 重庆康刻尔制药有限公司 一种盐酸吡格列酮格列美脲组合药物、片剂及其应用
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
KR101782119B1 (ko) * 2016-02-01 2017-10-23 주식회사 한독 테넬리글립틴 및 설포닐우레아계 약물을 포함하는 정제
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product
CN111410687B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种长效glp-1化合物
CN115721612B (zh) * 2021-08-26 2024-07-26 上海宣泰医药科技股份有限公司 一种恩扎卢胺固体制剂颗粒及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3152978B2 (ja) 1991-12-17 2001-04-03 塩野義製薬株式会社 二層錠およびその製造方法
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
BR9810142A (pt) 1997-06-18 2000-08-08 Smithkline Beecham Plc Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
TW585786B (en) * 1998-07-28 2004-05-01 Takeda Chemical Industries Ltd Lansoprazole-containing rapidly disintegrable solid pharmaceutical composition
CZ20011629A3 (cs) * 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
US6902744B1 (en) * 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
RU2177318C1 (ru) 2000-12-21 2001-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с антидиабетическим действием и способ ее получения
US20040147584A2 (en) * 2001-12-05 2004-07-29 Aventis Pharma S.A. 1,3-diarylprop-2-en-1-ones, compositions containing them and use thereof
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
EP1552832A1 (fr) 2002-07-11 2005-07-13 Takeda Pharmaceutical Company Limited Procede de production d'une preparation recouverte
US7332514B2 (en) * 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EP1588708A4 (fr) 2003-01-29 2006-03-01 Takeda Pharmaceutical Procede pour realiser une preparation enrobee
US20040147564A1 (en) 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
WO2004069229A1 (fr) * 2003-02-05 2004-08-19 Ipca Laboratories Limited Medicaments antidiabetiques a double liberation et procede de production de ceux-ci
WO2004091587A1 (fr) 2003-04-17 2004-10-28 Ipca Laboratories Limited Liberation multiple de medicaments anti-diabete et procede de production associe
BRPI0410555A (pt) 2003-06-06 2006-06-20 Takeda Pharmaceutical preparação sólida
EP1638554A1 (fr) * 2003-06-27 2006-03-29 Dr. Reddy's Research Foundation Compositions comprenant de la balaglitazone et d'autres composes antidiabetiques
WO2005009407A2 (fr) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Formulations pharmaceutiques d'olanzapine administrees par voie orale
CA2540225C (fr) * 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Preparation solide comprenant du pioglitazone, du glimepiride et un ester d'acide gras de polyoxyethylene sorbitan
JP4361461B2 (ja) * 2003-10-31 2009-11-11 武田薬品工業株式会社 固形製剤
EP1738754B1 (fr) * 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Preparation pharmaceutique solide
WO2005102290A1 (fr) 2004-04-22 2005-11-03 Ranbaxy Laboratories Limited Compositions pharmaceutiques formees d'un biguanide et d'une sulfonyluree

Also Published As

Publication number Publication date
ES2576258T3 (es) 2016-07-06
US8071130B2 (en) 2011-12-06
JP5179363B2 (ja) 2013-04-10
AU2006328328B2 (en) 2012-08-30
CA2633149A1 (fr) 2007-06-28
EP1962811B1 (fr) 2016-04-27
WO2007072992A3 (fr) 2007-12-06
TWI384985B (zh) 2013-02-11
HRP20160679T1 (hr) 2016-07-15
EP1962811A2 (fr) 2008-09-03
BRPI0620020A2 (pt) 2011-10-25
UA91729C2 (ru) 2010-08-25
RU2008130074A (ru) 2010-01-27
TW200731971A (en) 2007-09-01
US20090028939A1 (en) 2009-01-29
NO20083104L (no) 2008-09-19
KR20080080126A (ko) 2008-09-02
WO2007072992A2 (fr) 2007-06-28
CN101384251A (zh) 2009-03-11
CN101384251B (zh) 2014-09-03
GEP20115245B (en) 2011-06-27
IL191774A0 (en) 2008-12-29
NZ569071A (en) 2011-01-28
RU2426530C2 (ru) 2011-08-20
ZA200805147B (en) 2010-05-26
MY149306A (en) 2013-08-30
JP2009520681A (ja) 2009-05-28
AR058605A1 (es) 2008-02-13
PE20110019A1 (es) 2011-01-27
CA2633149C (fr) 2015-06-30
CR10032A (es) 2008-10-03
AU2006328328A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
MA30061B1 (fr) Preparation solide
TN2010000073A1 (fr) Compositon pharmaceutique contenant un derive de benzene substitue par glucopyranosyle
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA44206A (fr) Comprimé orodispersible comprenant estetrol
Fleming et al. The tissue renin–angiotensin system and intracellular signalling
MA30990B1 (fr) Antagonistes du recepteur de progesterone.
MA47399A (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
EP1624874A4 (fr) Derives d'acide 3-amino-4-phenylbutanoique en tant qu'inhibiteurs de dipeptidyl peptidase dans le cadre du traitement ou de la prevention du diabete
MA32548B1 (fr) Composition pharmaceutique a base de progesterone micronisee et ses utilisations
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
MA31779B1 (fr) Activateurs de glucokinase
MA29836B1 (fr) Proteines de fusion avec l'albumine
TN2009000138A1 (fr) Biaryl-ether-urees
MA31169B1 (fr) Preparation solide comprenant de l'alogliptine et de la pioglitazone
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA28140A1 (fr) Compositions et formes dosifiees pour favoriser l'absorption de la gabapentine et de la pregabaline
MA31471B1 (fr) Formulations d'anticorps
EP2101757A4 (fr) Composé pour le traitement ou la prévention de maladies en relation avec la prostate et compositions pharmaceutiques de système d'administration par le colon contenant ce composé
MA29273B1 (fr) Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur
MA31796B1 (fr) Composes organiques
MA35874B1 (fr) Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
WO2008017867A3 (fr) Composition orale solide antirétrovirale
MA29723B1 (fr) Composes